BTLA and neoplasm: The clinical trial in which the registration number was NCT00854399 revealed that BTLA detected in epithelial ovarian carcinoma (EOC) tissues can predict poor outcomes of patients, and chemotherapy combined with BTLA inhibitor can enhance immune activation and produces effective anti-tumor effects (Chen Y. L. et al., 2019).